Related Experiment Video

Updated: Jun 21, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

JNK1, a potential therapeutic target for hepatocellular carcinoma

Fei Chen1, Kevin Beezhold, Vince Castranova

  • 1Laboratory of Cancer Signaling and Epigenetics, Health Effects Laboratory Division, Pathology and Physiology Research Branch, National Institute for Occupational Safety and Health, 1095 Willowdale Road, Morgantown, WV 26505, USA. lfd3@cdc.gov

Biochimica Et Biophysica Acta
|July 14, 2009
PubMed

Insights

Hepatocellular carcinoma (HCC) is a deadly cancer. This review explores the role of c-Jun N-terminal kinase 1 (JNK1) in HCC development, suggesting JNK1 as a potential therapeutic target for this disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hepatocellular carcinoma (HCC) remains a significant global health challenge, ranking as the third leading cause of cancer mortality.
  • Current diagnostic and treatment strategies offer limited improvement in patient prognosis for HCC.
  • Understanding the molecular underpinnings of HCC initiation, maintenance, and progression is critical for developing effective therapies.

Purpose of the Study:

  • To review the multifaceted roles of c-Jun N-terminal kinase 1 (JNK1) in the pathogenesis of hepatocellular carcinoma (HCC).
  • To elucidate the association between JNK1 activity and the expression of key HCC signature genes.
  • To explore the potential of targeting JNK1 as a novel therapeutic strategy for HCC.

Main Methods:

  • Literature review of studies investigating the involvement of JNK1 in HCC.
  • Analysis of research linking JNK1 signaling pathways to HCC development and progression.
  • Synthesis of findings on the relationship between JNK1 and HCC-specific gene expression.

Main Results:

  • Evidence suggests a critical role for JNK1 in the molecular mechanisms driving human HCC.
  • JNK1 is closely associated with the expression patterns of genes characteristic of HCC.
  • Dysregulation of JNK1 signaling pathways contributes to HCC pathogenesis.

Conclusions:

  • JNK1 is implicated as a pivotal kinase in the development and progression of hepatocellular carcinoma.
  • Targeting JNK1 presents a promising avenue for the development of novel therapeutic interventions for HCC.
  • Further research into JNK1 pathways may unlock new treatment strategies for this fatal malignancy.

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...